- Market Capitalization, $K 3,700,502
- Shares Outstanding, K 255,207
- Annual Sales, $ 799,240 K
- Annual Income, $ 182,040 K
- 60-Month Beta -0.25
- Price/Sales 4.09
- Price/Cash Flow 8.06
- Price/Book 4.21
|Period||Period Low||Period High||Performance|
| || |
+0.68 (+4.92%)since 12/27/22
| || |
-2.12 (-12.76%)since 10/27/22
| || |
-10.75 (-42.57%)since 01/27/22
Buy on the dip. You've no doubt heard the expression plenty of times in the past. Granted, some stocks aren't good candidates to buy when they've pulled back. However, you can also often make a lot of...
All three are protected by sales of in-demand products, with more on the way.
These two companies are facing short-term issues that are likely to give way to long-term success.
MRVI earnings call for the period ending September 30, 2022.
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 15.63% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead...
It's positioned to benefit from the emergence of a new, long-term trend in biopharma.
LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.
MRVI earnings call for the period ending June 30, 2022.
|Maravai Lifesciences Holdings Inc Cl A|
|Pacer US Cash Cows 100 ETF|
|Smallcap ETF Vanguard|
|Nasdaq Biotechnology Ishares ETF|
|Smallcap Growth ETF Vanguard|
|Total Stock Market ETF Vanguard|
|3rd Resistance Point||15.96|
|2nd Resistance Point||15.36|
|1st Resistance Point||14.93|
|1st Support Level||13.90|
|2nd Support Level||13.30|
|3rd Support Level||12.87|